RedHill's RHB-204 shows comparable efficacy to RHB-104 in lab tests
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St set for lower open as Big Tech earnings rekindle AI spending worries, oil jumps
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
- Dollar hits fresh 40-year high versus yen, edges higher against euro
RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease
April 30, 2026 7:00 AM EDTRHB-2041Â is a next-generation optimized formulation of RedHill's oral RHB-1042, designed for enhanced tolerability, safety profile and patient adherence, that employs a groundbreaking Mycobacterium avium subspecies paratuberculosis (MAP)-targeted therapeutic approach for Crohn's disease (CD)
In its positive Phase 3 study, RHB-104 met the primary and key secondary endpoints with statistical significance, showing RHB-104 plus standard of care (SoC) to be 64% more effective than SoC alone, in treating CD compared to the placebo (standard of care only) group (p =... More
